The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for
safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in
subjects with heart failure, defined as New York Heart Association (NYHA) functional Class
III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP<1600 pg/ml despite being
treated with the appropriate heart failure guideline directed therapy, excluding subjects
eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).
The total trial duration is anticipated to be approximately 5 years; however, the duration of
an individual subject enrollment will depend on when he or she entered the trial.